congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Disease Area Tab
PublicationView
Poster
T-DXd
ESMO Breast 2024 | May 15-17, 2024
A health-related quality of life (QOL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) versus capecitabine (CAP) in patients with hormone receptor–positive (HR+), HER2-low metastatic breast cancer (mBC)
Oral
T-DXd
ESMO 2024 | September 13-17, 2024
A multicentre, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study (WJOG14320B)
Oral
T-DXd
ASCO 2024 | May 31 - June 4, 2024
A randomized study comparing electronic patient-reported outcomes monitoring with routine follow-up during trastuzumab deruxtecan treatment for inoperable or metastatic breast cancer patients: PRO-DUCE study
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
A real-world study of the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer (mBC) among racial and ethnic minorities and older populations in the United States: Trial in progress (TiP)
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
A retrospective study to investigate the prevalence and treatment outcomes of HER2-low unresectable/metastatic breast cancer in Taiwan — the RetroBC-HER2L-TW study
Poster
T-DXd
Miami Breast 2024 | March 7-10, 2024
Addressing barriers to identifying HER2-low metastatic breast cancer patients in a large
community oncology practice
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
Clinical characteristics of patients with HER2+ unresectable or metastatic breast cancer: HER2 REAL Asia cohort
Poster
T-DXd
AACR 2024 | April 5-10, 2024
Concordance between the DESTINY-Breast04 clinical trial assay (4B5[CDx]) and other HER2 IHC assays for HER2-low breast cancer in real-world practice: First phase of a large-scale, multicenter global ring study
Poster
T-DXd
SABCS 2024 | December 10-13, 2024
Concordance between the DESTINY-Breast04/06
VENTANA 4B5 HER2 IHC clinical trial assay
and other comparator assays for HER2-low
breast cancer: Overall results of a large-scale,
multicenter, global ring study
Oral
Dato-DXd
JSMO 2024 | February 22-24, 2024
Dato-DXd vs chemotherapy for patients with inoperable/metastatic HR+/HER2– breast cancer: TROPION-Breast01 East Asian subset analysis